Clinical trial
Canadian Pegvisomant Compassionate Study In Acromegalic Patients
NCT00151437 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00151437 |
|---|---|
| Title | Canadian Pegvisomant Compassionate Study In Acromegalic Patients |
| Official title | A Multi-Center, Open-Label Study For The Compassionate Use Of Pegvisomant In Acromegalic Patients Refractory To Conventional Therapy and For Patients Who Received The Product During The Clinical Development Program. |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Acromegaly |
| Intervention type | Drug, Procedure |
| Interventions | Pegvisomant treatment, Medical History, demographics, Sign and symptoms: questionnaire, Blood tests: IGF-1, AST/ALT/ALP/TBIL, GTT, MRI |
| Enrollment | 30 |
| Start date | Nov 1, 2004 |
| Completion | Apr 1, 2007 |
| First posted | Sep 9, 2005 |
| Last update posted | Apr 24, 2008 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: